Ashurst advises Treefrog Therapeutics on a €30 million financing

Ashurst has assisted Treefrog Therapeutics, a leading player in the biotechnology sector, in securing a major €30 million financing granted by the European Investment Bank (EIB). This transformative transaction supports Treefrog Therapeutics’ growth strategy and confirms its position as a pioneer in the development of innovative cell therapy solutions.

With this financing, Treefrog Therapeutics will take a new step in its development. This financial support will enable the company to accelerate their advancement to the clinic of their Parkinson’s disease cell therapy program, in addition to reinforcing their internal pipeline with new assets and R&D in other therapeutic areas. Treefrog will thus be able to speed up the market launch of its innovative cell therapies while pursuing its international ambitions.

The Ashurst team was led by François Hellot, assisted by Raphaël Chekroun in corporate, and included Pierre Roux, Kevin Perraudin, and Milan Czajka financing.